Showing results (571-580 of 587) with videos related to
Sort By:
Pageof 59
Cell Reports. Medicine|May 7, 2025
Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutationYan Xu, James Chih-Hsin Yang, Yanqiu Zhao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2017
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET RegistryOliver Gautschi, Julie Milia, Thomas Filleron, et al.Molecular Oncology|September 13, 2021
The Porto European Cancer Research Summit 2021Ulrik Ringborg, Anton Berns, Julio E Celis, et al.The New England Journal of Medicine|August 27, 2020
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung CancerAlexander Drilon, Geoffrey R Oxnard, Daniel S W Tan, et al.The Lancet. Oncology|October 2, 2025
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort studyAlessandro Di Federico, Kaiwen Wang, Monica F Chen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2025
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)James Chih-Hsin Yang, Mengzhao Wang, Ludovic Doucet, et al.The New England Journal of Medicine|September 9, 2025
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLCJames Chih-Hsin Yang, Shun Lu, Hidetoshi Hayashi, et al.Oncotarget|May 7, 2015
A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancerVladimir Lazar, Eitan Rubin, Stephane Depil, et al.The New England Journal of Medicine|June 26, 2024
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLCByoung C Cho, Shun Lu, Enriqueta Felip, et al.Cancer Discovery|August 5, 2022
Escherichia coli-Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder CancerAnne-Gaëlle Goubet, Leonardo Lordello, Carolina Alves Costa Silva, et al.Pageof 59